| Literature DB >> 29606320 |
J Ciron1, B Audoin2, B Bourre3, D Brassat4, F Durand-Dubief5, D Laplaud6, E Maillart7, C Papeix7, S Vukusic8, H Zephir9, R Marignier10, N Collongues11.
Abstract
There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue therapy. Nevertheless, considerable heterogeneity still exists concerning the pre-treatment work-up, the vaccinations required before and under treatment, the number and dosage of infusions, prevention of the risk of infusion-related reactions, prevention of infections under treatment, and frequency of therapeutic cycles. Thanks to a collaborative work among NMO-SD experts belonging to the NOMADMUS project, we provide here recommendations for all these topics concerning RTX use in NMO-SD.Entities:
Keywords: Guidelines; Neuromyelitis optica; Recommendations; Rituximab; Treatment
Mesh：
Substances：
Year: 2018 PMID： 29606320 DOI： 10.1016/j.neurol.2017.11.005
Source DB: PubMed Journal: Rev Neurol (Paris) ISSN： 0035-3787 Impact factor: 2.607